Intellia Therapeutics, Inc.
GB ˙ LSE ˙ US45826J1051
14,82 $ ↑1,89 (14,61%)
2026-06-04
AKTIENPREIS
SecurityGB:0JBU / Intellia Therapeutics, Inc.
InstitutionBlackRock, Inc.
Latest Disclosed Ownership8,453,014 shares
Ownership 8.20%
BlackRock, Inc. ownership in 0JBU / Intellia Therapeutics, Inc.

2025-04-17 - BlackRock, Inc. has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 8,453,014 shares of Intellia Therapeutics, Inc. (GB:0JBU). This represents 8.2 percent ownership of the company. In their previous filing dated 2024-01-08 , BlackRock, Inc. had reported owning 9,010,695 shares, indicating a decrease of -6.19 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2025-04-17 2025-04-17 13G/A 9,010,695 8,453,014 -6.19 8.20 -18.81
2024-01-08 2024-01-08 13G/A 7,254,921 9,010,695 24.20 10.10 16.09
2023-01-25 2023-01-25 13G 5,620,376 7,254,921 29.08 8.70 14.47
2022-02-03 2022-02-03 13G/A 5,052,845 5,620,376 11.23 7.60 -11.63
2021-01-29 2021-01-29 13G/A 3,645,230 5,052,845 38.62 8.60 14.67
2020-02-05 2020-02-05 13G/A 2,868,738 3,645,230 27.07 7.50 13.64
2019-02-08 2019-02-08 13G 2,868,738 2,868,738 0.00 6.60 0.00
2019-02-07 2019-02-07 13G 2,868,738 6.60

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 12,155,806 1,878,957 18.28 155,837 68.68 0.0027
2026-02-12 2025-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 10,276,849 1,001,032 10.79 92,389 -42.33 0.0016
2025-11-12 2025-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 9,275,817 -751,358 -7.49 160,193 70.32 0.0028
2025-08-12 2025-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 10,027,175 -529,015 -5.01 94,055 25.32 0.0018
2025-05-02 2025-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 10,556,190 -301,503 -2.78 75,055 -40.72 0.0016
2025-02-07 2024-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 10,857,693 1,084,951 11.10 126,601 -36.96 0.0026
2024-11-13 2024-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 9,772,742 175,135 1.82 200,830 -6.50 0.0042
2024-08-13 2024-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 9,597,607 488,339 5.36 214,794 -14.29 0.0049
2024-05-10 2024-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 9,109,268 98,573 1.09 250,596 -8.79 0.0058
2024-02-13 2023-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 9,010,695 877,905 10.79 274,736 6.84 0.0070
2023-11-13 2023-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 8,132,790 77,827 0.97 257,159 -21.71 0.0074
2023-08-11 2023-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 8,054,963 706,344 9.61 328,481 19.93 0.0091
2023-05-12 2023-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 7,348,619 93,373 1.29 273,883 8.20 0.0081
2023-02-13 2022-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 7,255,246 1,127,106 18.39 253,136 -26.18 0.0079
2022-11-14 2022-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 6,128,140 240,741 4.09 342,930 12.54 0.0117
2022-08-12 2022-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 5,887,399 285,660 5.10 304,731 -25.14 0.0098
2022-05-12 2022-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 5,601,739 -18,637 -0.33 407,079 -38.74 0.0110
2022-02-10 2021-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 5,620,376 89,381 1.62 664,553 -10.44 0.0169
2021-11-09 2021-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 5,530,995 565,430 11.39 741,985 -7.71 0.0208
2021-08-11 2021-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 4,965,565 -306,061 -5.81 803,974 90.03 0.0224
2021-05-07 2021-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 5,271,626 218,781 4.33 423,074 53.91 0.0124
2021-02-05 2020-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 5,052,845 -592,164 -10.49 274,876 144.94 0.0088
2020-11-06 2020-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 5,645,009 594,183 11.76 112,224 5.70 0.0041
2020-08-14 2020-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 5,050,826 1,258,528 33.19 106,168 128.91 0.0042
2020-05-01 2020-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 3,792,298 147,068 4.03 46,379 -13.27 0.0023
2020-02-13 2019-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 3,645,230 64,632 1.81 53,476 11.87 0.0021
2019-11-08 2019-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 3,580,598 190,331 5.61 47,800 -13.87 0.0020
2019-08-22 2019-06-30 13F/A-1 INTELLIA THERAPEUTICS COM 45826J105 3,390,267 208,548 6.55 55,499 2.13 0.0024
2019-08-13 2019-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 3,390,267 208,548 55,499
2019-05-09 2019-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 3,181,719 312,981 10.91 54,343 38.78 0.0024
2019-02-08 2018-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 2,868,738 124,341 4.53 39,158 -50.15 0.0020
2018-11-09 2018-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 2,744,397 188,098 7.36 78,545 12.30 0.0034
2018-08-09 2018-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 2,556,299 833,337 48.37 69,940 92.47 0.0032
2018-05-09 2018-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 1,722,962 12,015 0.70 36,338 10.50 0.0017
2018-02-09 2017-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 1,710,947 31,662 1.89 32,885 -21.20 0.0016
2017-11-14 2017-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 1,679,285 3,949 0.24 41,730 55.67 0.0021
2017-08-10 2017-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 1,675,336 731,992 77.60 26,806 101.66 0.0014
2017-05-12 2017-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 943,344 942,943 235,147.88 13,293 265,760.00 0.0007
2017-02-10 2016-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 401 0 0.00 5 -28.57 0.0000
2016-11-08 2016-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 401 -2,063 -83.73 7 -86.79 0.0000
2016-08-10 2016-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 2,464 2,464 53 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.